Home › Opioid Overdose › NCT07176351
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic: A Pilot Study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Able to provide written informed consent in English or Spanish * Current or history of DSM-5 moderate-to-severe OUD per Rapid Opioid Use Disorder Assessment (ROUDA) * Not planning to move out of state or to new location during study enrollment. Exclusion Criteria: * Medical or psychiatric disorders making participation unsafe or regular follow-up unlikely, (such as suicidal ideation or pre-existing moderate to severe hepatic impairment) * Persons who are pregnancy * People who show violent or threatening behavior toward staff and/or others * Allergy, hypersensitivity, or medical contraindication to medication (the BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in persons with latex-sensitivity)
About the study
This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC).
Participants who are interested in initiating monthly or weekly injections of subcutaneous XR-B (BRIXADI) as a treatment for their OUD will be enrolled in a 6-month study assessing the acceptability and feasibility of receiving XR-B on an MPC.
What is being tested
- Buprenorphine (drug)
Sponsor: Yale University · Participants: 60 · Started: Sep 23, 2026
Contact the study team
- Sandra Springer, MD · Phone: 203-687-6680
- Angela Di Paola · Phone: +1 475-306-1608
Official record on ClinicalTrials.gov — NCT07176351
Locations in the U.S.
| Connecticut | Yale School of Medicine, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.